Oncology | Phase I Developments | SWITZERLAND

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Laekna Acquires Exclusive Global Rights to Clinical-Stage Cancer Asset

Lead Product(s): FAZ053

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Laekna Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement March 24, 2020

Details:

Laekna now has exclusive rights to develop and commercialize the PD-L1 oncology asset. With this move, the company aims to advance clinical research and introduce pioneering new drugs to patients.

Debiopharm

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Debiopharm Advances into the Highly Anticipated Clinical Phase for their Potent WEE1 Inhibitor

Lead Product(s): Debio 0123

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 05, 2020

Details:

Debio 0123 starts first-in-human, dose escalation phase I clinical trial assessing the safety and efficacy of the compound in combination with carboplatin to treat refractory solid tumors.

Ionctura

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

iOnctura Announces First Patient Dosed in a Phase I Clinical Study of its Novel Highly Selective PI3K? Inhibitor

Lead Product(s): IOA-244

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 26, 2020

Details:

The phase I study will enrol approximately 60 patients with solid tumours that overexpress PI3K? and are burdened by immune cells of the suppressor phenotype that are sensitive to PI3K? inhibition.

Ionctura

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

iOnctura Raises EUR 15 Million in Series A Financing to Progress its Pipeline into Clinical Development

Lead Product(s): IOA-244

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: INKEF Capital

Deal Size: $16.5 million Upfront Cash: Undisclosed

Deal Type: Series A Financing January 23, 2020

Details:

iOnctura will use the proceeds of the Series A to move its lead molecule IOA-244, a highly selective PI3K?-inhibitor, into a Phase I trial in solid tumours and its second program, IOA-289, an ATX-inhibitor, through IND enabling studies.

Find

Find Oncology Drugs in Phase I Clinical Development in SWITZERLAND

Switzerland

A collaboration with SCORR Marketing

Product Type

Companies

Novartis Pharmaceuticals Corporation

Laekna Acquires Exclusive Global Rights to Clinical-Stage Cancer Asset

Debiopharm

Debiopharm Advances into the Highly Anticipated Clinical Phase for their Potent WEE1 Inhibitor

Ionctura

iOnctura Announces First Patient Dosed in a Phase I Clinical Study of its Novel Highly Selective PI3K? Inhibitor

Ionctura

iOnctura Raises EUR 15 Million in Series A Financing to Progress its Pipeline into Clinical Development